1. Home
  2. RSVR vs ALT Comparison

RSVR vs ALT Comparison

Compare RSVR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reservoir Media Inc.

RSVR

Reservoir Media Inc.

N/A

Current Price

$9.89

Market Cap

673.7M

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.11

Market Cap

573.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSVR
ALT
Founded
2007
1997
Country
United States
United States
Employees
N/A
57
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
673.7M
573.8M
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
RSVR
ALT
Price
$9.89
$3.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$11.50
$17.67
AVG Volume (30 Days)
45.6K
5.0M
Earning Date
05-27-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
8.33
25.37
EPS
0.13
N/A
Revenue
$175,664,491.00
$41,000.00
Revenue This Year
$10.95
N/A
Revenue Next Year
$4.16
N/A
P/E Ratio
$75.15
N/A
Revenue Growth
10.69
105.00
52 Week Low
$7.07
$2.56
52 Week High
$13.39
$6.44

Technical Indicators

Market Signals
Indicator
RSVR
ALT
Relative Strength Index (RSI) 47.08 56.90
Support Level $9.85 $2.80
Resistance Level $10.34 $3.32
Average True Range (ATR) 0.34 0.14
MACD -0.03 0.01
Stochastic Oscillator 42.58 72.50

Price Performance

Historical Comparison
RSVR
ALT

About RSVR Reservoir Media Inc.

Reservoir Media Inc is an independent music company. The company operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the U.S. Music Publishing segment engaged in the acquisition of interests in music catalogs to earn royalties and signing songwriters to agreements of future delivery of songs. The Recorded Music segment involve the acquisition of sound recording catalogs and the discovery and development of recording artists and the marketing, distribution, sale and licensing of the music catalog.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: